文献速递术前评估与围术期医学疼痛医学

围术期纳曲酮管理:围术期疼痛与成瘾跨学科网络的范围综述

Perioperative Naltrexone Management: A Scoping Review by the Perioperative Pain and Addiction Interdisciplinary Network.
PubMed 文献 · Anesthesiology · 2024-01-01

所有指南均推荐术前停用纳曲酮,但均未基于系统文献检索或Delphi流程制定;缺乏高质量证据,继续或停用纳曲酮的风险获益尚不明确。

要点

  • 所有指南推荐术前停用纳曲酮,不论剂量、适应症或给药途径。
  • 无研究关注围术期纳曲酮管理下成瘾康复的维持。
  • 现有证据质量低,停用纳曲酮对有回归使用风险者需强指征。

核心结论

  • 当前对围术期继续或停用纳曲酮的风险与获益理解有限,缺乏高质量证据。
  • 对有阿片或酒精回归使用风险的患者,停用纳曲酮应有强指征。

研究设计与样本

  • 范围综述,系统检索Medline、Medline In-Process、Embase、PsycINFO和Web of Science。

主要发现

  • 尽管纳曲酮用于酒精使用障碍和慢性疼痛,但无临床研究、病例报告或指南涉及这些人群的围术期纳曲酮使用。
  • 围术期疼痛缓解因纳曲酮剂量、给药途径、末次给药时间和基础物质使用障碍而异。
  • 无研究评论围术期纳曲酮管理背景下患者物质使用障碍康复的维持。

关键数值与推荐

  • 所有指南文件推荐术前停用纳曲酮, irrespective of dose, indication, or route of administration。
  • 无指南文件基于系统文献检索或Delphi流程设计。

临床怎么用

  • 围术期纳曲酮管理应个体化,权衡急性疼痛管理与成瘾康复维持。
  • 停用纳曲酮前需评估患者回归使用阿片或酒精的风险,确保强指征。

局限性

  • 缺乏高质量证据,现有指南未基于系统检索或Delphi流程。
  • 无研究涉及酒精使用障碍和慢性疼痛人群的围术期纳曲酮管理。
  • 无研究评论围术期纳曲酮管理下成瘾康复的维持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Substance use disorders, including alcohol use disorder, are a public health concern that affect more than 150 million people globally. The opioid antagonist naltrexone is being increasingly prescribed to treat opioid use disorder, alcohol use disorder, and chronic pain. Perioperative management of patients on naltrexone is inconsistent and remains a controversial topic, with mismanagement posing a significant risk to the long-term health of these patients. This scoping review was conducted to identify human studies in which the perioperative management of naltrexone was described. This review includes a systematic literature search involving Medline, Medline In-Process, Embase, PsycINFO, and Web of Science. Seventeen articles that describe perioperative naltrexone management strategies were included, including thirteen guidelines, one case report, and three randomized trials. Despite its use in patients with alcohol use disorder and chronic pain, no clinical studies, case reports, or guidelines addressed naltrexone use in these clinical populations. All of the guideline documents recommended the preoperative cessation of naltrexone, irrespective of dose, indication, or route of administration. None of these guideline documents were designed on the basis of a systematic literature search or a Delphi protocol. As described by the primary studies, perioperative pain relief varied depending on naltrexone dose and route of administration, time since last naltrexone administration, and underlying substance use disorder. None of the studies commented on the maintenance of recovery for the patient's substance use disorder in the context of perioperative naltrexone management. The current understanding of the risks and benefits of continuing or stopping naltrexone perioperatively is limited by a lack of high-quality evidence. In patients with risk factors for return to use of opioids or alcohol, the discontinuation of naltrexone should have a strong rationale. Future studies and guidelines should seek to address both acute pain management and maintaining recovery when discussing perioperative naltrexone management strategies.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Goel A, Kapoor B, Wu M, et al. Perioperative Naltrexone Management: A Scoping Review by the Perioperative Pain and Addiction Interdisciplinary Network. Anesthesiology. 2024. PMID: 38980158. doi:10.1097/ALN.0000000000005040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。